Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays

Hyams D.M.; Bareket-Samish A.; Rocha J.E.B.; Diaz-Botero S.; Franco S.; Gagliato D.; Gomez H.L.; Korbenfeld E.; Krygier G.; Mattar A.; De Pierro A.N.; Borrego M.R.; Villarreal C. · Journal of Surgical Oncology (2024) · DOI: 10.1002/jso.27692

Resumen

Gene expression assays (GEAs) can guide treatment for early-stage breast cancer. Several large prospective randomized clinical trials, and numerous additional studies, now provide new information for selecting an appropriate GEA. This systematic review builds upon prior reviews, with a focus on five widely commercialized GEAs (Breast Cancer Index®, EndoPredict®, MammaPrint®, Oncotype DX®, and Prosigna®). The comprehensive dataset available provides a contemporary opportunity to assess each GEA's utility as a prognosticator and/or predictor of adjuvant therapy benefit.

Instituciones: Universidad Ricardo Palma